What can we help you find?

August 7, 2019 3:39 pm ET

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Peter Dannenbaum has been promoted to vice president, Investor Relations, effective Aug. 19, 2019. Teri Loxam, senior vice president, Investor Relations and Global Communications, will be leaving Merck to become chief financial officer of SQZ Biotech.

“Merck has benefited from Teri’s leadership and skilled and principled approach to communicating with its many constituencies including those in the financial community. She will be missed personally and professionally,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “She leaves behind a capable and experienced investor relations team under the leadership of Peter Dannenbaum.”

Mr. Dannenbaum joined Merck’s investor relations team in July 2017. Prior to this, Mr. Dannenbaum was a healthcare-focused portfolio manager and the director of research at CDPQ New York, a subsidiary of the Caisse de Depot et Placement du Quebec, for nine years. Mr. Dannenbaum also served as a healthcare analyst and portfolio manager at Morgan Stanley Investment Management and at John A. Levin & Company.

About Merck

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world – including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2018 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Media:
Pamela Eisele
(267) 305-3558

Jennifer Mauer
(908) 740-1801

Investor:
Peter Dannenbaum
(908) 740-1037

Michael DeCarbo
(908) 740-1807